KR20160104101A - 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법 - Google Patents

신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법 Download PDF

Info

Publication number
KR20160104101A
KR20160104101A KR1020167023212A KR20167023212A KR20160104101A KR 20160104101 A KR20160104101 A KR 20160104101A KR 1020167023212 A KR1020167023212 A KR 1020167023212A KR 20167023212 A KR20167023212 A KR 20167023212A KR 20160104101 A KR20160104101 A KR 20160104101A
Authority
KR
South Korea
Prior art keywords
leu
thr
glu
ser
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167023212A
Other languages
English (en)
Korean (ko)
Inventor
스테펜 브랜드
치-시웅 초우
머레이 무-영
Original Assignee
아고스 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아고스 쎄라퓨틱스, 인코포레이티드 filed Critical 아고스 쎄라퓨틱스, 인코포레이티드
Publication of KR20160104101A publication Critical patent/KR20160104101A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
KR1020167023212A 2008-05-23 2009-05-22 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법 Ceased KR20160104101A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12870908P 2008-05-23 2008-05-23
US61/128,709 2008-05-23
PCT/US2009/003174 WO2009142759A1 (en) 2008-05-23 2009-05-22 Novel soluble cd83 polypeptides, formulations and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107028713A Division KR101679084B1 (ko) 2008-05-23 2009-05-22 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법

Publications (1)

Publication Number Publication Date
KR20160104101A true KR20160104101A (ko) 2016-09-02

Family

ID=41340432

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167023212A Ceased KR20160104101A (ko) 2008-05-23 2009-05-22 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법
KR1020107028713A Expired - Fee Related KR101679084B1 (ko) 2008-05-23 2009-05-22 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107028713A Expired - Fee Related KR101679084B1 (ko) 2008-05-23 2009-05-22 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법

Country Status (12)

Country Link
US (1) US20110182903A1 (cg-RX-API-DMAC7.html)
EP (1) EP2288387B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520959A (cg-RX-API-DMAC7.html)
KR (2) KR20160104101A (cg-RX-API-DMAC7.html)
CN (1) CN102036690B (cg-RX-API-DMAC7.html)
AU (1) AU2009249540B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0913577B1 (cg-RX-API-DMAC7.html)
CA (1) CA2725198A1 (cg-RX-API-DMAC7.html)
IL (1) IL209207A (cg-RX-API-DMAC7.html)
MX (1) MX2010012576A (cg-RX-API-DMAC7.html)
RU (1) RU2535340C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009142759A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200030444A (ko) 2018-09-12 2020-03-20 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CN103243119B (zh) * 2013-05-20 2016-03-30 中国科学技术大学 可溶性cd83的表达和制备方法
CA3042683A1 (en) 2016-11-07 2018-05-11 Coimmune, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
BR112019020214A2 (pt) * 2017-04-01 2020-04-22 Avm Biotechnology Llc substituição do pré-condicionamento citotóxico antes da imunoterapia celular
EP3895723A1 (en) 2020-04-16 2021-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Scd83 for wound healing, hair growth, and skin and hair care
DE102024110866A1 (de) 2024-04-18 2025-10-23 Christian Arnold Pharmazeutische Zusammensetzung zur Heilung einer Wunde

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US6197930B1 (en) * 1997-08-26 2001-03-06 Zymogenetics, Inc. Adipocyte-specific protein homologs
ATE297217T1 (de) 1999-10-27 2005-06-15 Alexandra Lucas Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2003282550C1 (en) * 2002-10-09 2008-09-25 Tolerx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
EP1422241A1 (en) * 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
EP2051987B1 (en) * 2006-08-18 2014-11-19 Argos Therapeutics, Inc. Use of cd83 in combination therapies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200030444A (ko) 2018-09-12 2020-03-20 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
BRPI0913577B1 (pt) 2022-05-31
EP2288387A4 (en) 2011-04-27
IL209207A (en) 2014-05-28
WO2009142759A1 (en) 2009-11-26
AU2009249540B9 (en) 2014-09-18
EP2288387A1 (en) 2011-03-02
KR20110018381A (ko) 2011-02-23
BRPI0913577A2 (pt) 2020-08-18
AU2009249540A8 (en) 2011-01-20
HK1155066A1 (en) 2012-05-11
AU2009249540B2 (en) 2014-07-03
RU2010152553A (ru) 2012-06-27
JP2011520959A (ja) 2011-07-21
AU2009249540A1 (en) 2009-11-26
IL209207A0 (en) 2011-01-31
US20110182903A1 (en) 2011-07-28
EP2288387B1 (en) 2013-02-13
CN102036690A (zh) 2011-04-27
CA2725198A1 (en) 2009-11-26
RU2535340C2 (ru) 2014-12-10
CN102036690B (zh) 2013-11-06
MX2010012576A (es) 2011-04-05
KR101679084B1 (ko) 2016-11-24

Similar Documents

Publication Publication Date Title
KR101679084B1 (ko) 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법
AU2002305716B2 (en) Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
JP2009240311A (ja) 活性化されたｔ細胞の表面上のレセプタ：ａｃｔ−４
JPH09509826A (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
CA2658000C (en) Use of cd83 in combination therapies
JP2010279365A (ja) 修飾したヒト胸腺ストローマ細胞リンホポエチン
JP2018522547A (ja) Ｉｌ−３７バリアント
EP1525221A1 (en) Conjugate of notch signalling pathway modulators and their use in medical treatment
WO2006011485A1 (ja) アミロイドペプチドの凝集を抑制する蛋白質とその作用
AU2021336259A1 (en) Interleukin-2 muteins and uses thereof
HK1155066B (en) Novel soluble cd83 polypeptides, formulations and methods of use
CN115073607A (zh) Tnfr2与baff受体的融合蛋白
CA2332379A1 (en) Molecules associated with apoptosis
WO1998041634A1 (en) Human growth and differentiation protein
EA042572B1 (ru) Мутеины il-2 и способы их применения
HK1262138A1 (en) Uses of soluble ctla4 mutant molecules
HK1120221B (en) Uses of soluble ctla4 mutant molecules

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160824

Application number text: 1020107028713

Filing date: 20101221

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160923

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161020

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170425

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161020

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I